Roth Capital steps to the sidelines on Peregrine Pharmaceuticals (PPHM -79%), downgrading it to...

Roth Capital steps to the sidelines on Peregrine Pharmaceuticals (PPHM -79%), downgrading it to Neutral and removing it from its Focus List due to the uncertainty over the discrepancies in its Phase II study of bavituximab. The firm also skewered its price target on the shares, slashing it to $0.70 from $9.

From other sites
Comments (8)
  • TruffelPig
    , contributor
    Comments (4208) | Send Message
    These guys are FAST! First the increased the price target from low to 3 to 5 to 9 and now all the way back! Impressive.
    24 Sep 2012, 03:56 PM Reply Like
  • SoldHigh
    , contributor
    Comments (991) | Send Message
    Wait until AFTER the stock tanks 80% to d/g. May as well give us yesterday's news, too.


    So worthless.
    24 Sep 2012, 03:56 PM Reply Like
  • dingying85
    , contributor
    Comments (11) | Send Message
    but is $PPHM buyable now?
    24 Sep 2012, 06:35 PM Reply Like
  • rosputko
    , contributor
    Comments (3) | Send Message
    com'on folks. The recent news from PPHM that a recent third party blind test has inconsistencies in them is a bit too far fetched! I ask myself what are the chances that a third party firm would deliver a report in which its data would be discovered to be flawed only a few days after PPHM said the data was positive. I think it is highly doubtful. Also why would Roth Capital and a slew of other investment firms would upgrade the stock only a few days to weeks ago and then to quickly go the other way. Don't such firms carefully study all the angles, all data before placing their name on those upgrades? Here is my take.


    They pumped and then dumped the stock and are simply waiting to pick up the stock at 75% discount form just one trading day ago. The stock market is rigged and only the big boys that borrow money at 0% from the corrupt FED can afford to gamble on the stock market. IN a month or so PPHM will be on the rise once again. I lost 6K before I woke up this morning and before the market even opened. I'll hang on to my shares and just wait until they study the "discrepancies" and issue a Press release saying it was not as bad as they figured. There is simply way too hundreds of million bet on this lung cancer drug for it to go belly up. Then again if I am wrong I'm out of most of my investment in it anyway. The only way to go is up.
    24 Sep 2012, 06:37 PM Reply Like
  • dingying85
    , contributor
    Comments (11) | Send Message
    could be just kill those who carry margins and then they bring it up? These kind of biotech or biopharm stocks are too risky
    24 Sep 2012, 06:40 PM Reply Like
  • pegasusken
    , contributor
    Comments (4) | Send Message
    can someone explain to me how 13.9 million shares traded in the first minute without a delayed opening? Where did that many buyers come from so quickly.?Also, any thoughts on how damaging this contractor error is?
    24 Sep 2012, 07:30 PM Reply Like
  • jwb429
    , contributor
    Comments (3) | Send Message
    I have owned this stock or its options for many years , buying high and selling low or buying low and selling lower. The only people making money on this crap are the officers with their inflated salaries.
    Maybe now they wlll have another 1 for 10 reverse split. URGGHHH!
    I see this stock going to $.001, but I am usually wrong about this so called compnay
    24 Sep 2012, 11:14 PM Reply Like
  • newpy
    , contributor
    Comment (1) | Send Message
    Typical Roth maneuver - pump it up almost daily, raise the target price to 9 just before the fraud is unveiled. Wonder if they planned to do a reg. direct deal in it - a real screw job. We've been 'Rothed". Has anyone ever questioned the analyst? Seems to be in a lot of crap.
    30 Sep 2012, 04:05 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs